1
|
Duivenvoorden WC, Margel D, Subramony Gayathri V, Duceppe E, Yousef S, Naeim M, Khajehei M, Hopmans S, Popovic S, Ber Y, Heels-Ansdell D, Devereaux PJ, Pinthus JH. Follicle-Stimulating Hormone Exacerbates Cardiovascular Disease in the Presence of Low or Castrate Testosterone Levels. JACC Basic Transl Sci 2024; 9:364-379. [PMID: 38559622 PMCID: PMC10978407 DOI: 10.1016/j.jacbts.2023.10.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Accepted: 10/17/2023] [Indexed: 04/04/2024]
Abstract
Low testosterone (T), common in aging men, associates with cardiovascular disease. We investigated whether follicle-stimulating hormone (FSH), which is affected by T, modulates the cardiovascular effects associated with low T or castration. FSHβ-/-:low-density lipoprotein receptor (LDLR)-/- mice, untreated or castrated (orchiectomy, gonadotropin-releasing hormone agonist or antagonist), demonstrated significantly less atherogenesis compared with similarly treated LDLR-/- mice, but not following FSH delivery. Smaller plaque burden in LDLR-/- mice receiving gonadotropin-releasing hormone antagonists vs agonists were nullified in FSHβ-/-:LDLR-/- mice. Atherosclerotic and necrotic plaque size and macrophage infiltration correlated with serum FSH/T. In patients with prostate cancer, FSH/T following androgen-deprivation therapy initiation predicted cardiovascular events. FSH facilitates cardiovascular disease when T is low or eliminated.
Collapse
Affiliation(s)
- Wilhelmina C.M. Duivenvoorden
- Department of Surgery, Division of Urology, Faculty of Medicine, McMaster University, Hamilton, Ontario, Canada
- Research Institute of St. Joe’s Hamilton, Hamilton, Ontario, Canada
| | - David Margel
- Department of Urology, Rabin Medical Center, Petach Tikva, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | | | - Emmanuelle Duceppe
- Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
- Department of Medicine, Centre Hospitalier de l'Universite de Montréal, Montréal, Québec, Canada
| | - Sadiya Yousef
- Research Institute of St. Joe’s Hamilton, Hamilton, Ontario, Canada
| | - Magda Naeim
- Research Institute of St. Joe’s Hamilton, Hamilton, Ontario, Canada
| | - Mohammad Khajehei
- Department of Surgery, Division of Urology, Faculty of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Sarah Hopmans
- Department of Surgery, Division of Urology, Faculty of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Snezana Popovic
- Department of Pathology and Molecular Medicine, Faculty of Medicine, McMaster University, Hamilton, Ontario, Canada
| | - Yaara Ber
- Department of Urology, Rabin Medical Center, Petach Tikva, Israel
| | - Diane Heels-Ansdell
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
| | - Philip J. Devereaux
- Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
- Department of Medicine, Centre Hospitalier de l'Universite de Montréal, Montréal, Québec, Canada
| | - Jehonathan H. Pinthus
- Department of Surgery, Division of Urology, Faculty of Medicine, McMaster University, Hamilton, Ontario, Canada
- Research Institute of St. Joe’s Hamilton, Hamilton, Ontario, Canada
| |
Collapse
|
2
|
Duivenvoorden WCM, Naeim M, Hopmans SN, Yousef S, Werstuck GH, Dason S, Pinthus JH. Correction: Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE -/-:Ins2 +/Akita mouse model. Prostate Cancer Prostatic Dis 2021; 25:596. [PMID: 34413483 DOI: 10.1038/s41391-021-00408-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Wilhelmina C M Duivenvoorden
- Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada.,Research Institute of St. Joe's, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
| | - Magda Naeim
- Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada
| | - Sarah N Hopmans
- Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada
| | - Sadiya Yousef
- Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada
| | - Geoff H Werstuck
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada.,Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada
| | - Shawn Dason
- Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada.,Department of Urology, The Ohio State University, Columbus, OH, USA
| | - Jehonathan H Pinthus
- Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada. .,Research Institute of St. Joe's, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
| |
Collapse
|
3
|
Affiliation(s)
- A Kamran
- School of Medicine and Allied Medical Sciences, Ardabil University of Medical Sciences, Ardabil, Iran
| | - M Naeim
- Social Determinants of Health Research Center, Ardabil University of Medical Sciences, Ardabil, Iran
| | - A Rezaeisharif
- Department of Counseling, University of Mohaghegh Ardebili, Ardebil, Iran
| |
Collapse
|
4
|
Kamran A, Naeim M. Behavioural change theories: a necessity for managing COVID-19. Public Health 2020; 197:e4-e5. [PMID: 33468323 PMCID: PMC7574837 DOI: 10.1016/j.puhe.2020.10.010] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2020] [Revised: 09/30/2020] [Accepted: 10/06/2020] [Indexed: 11/28/2022]
Affiliation(s)
- A Kamran
- Social Determinants of Health Research Center, Ardabil University of Medical Sciences, Ardabil, Iran
| | - M Naeim
- Social Determinants of Health Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.
| |
Collapse
|
5
|
Duivenvoorden WCM, Naeim M, Hopmans SN, Yousef S, Werstuck GH, Dason S, Pinthus JH. Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE -/-:Ins2 +/Akita mouse model. Prostate Cancer Prostatic Dis 2020; 24:389-397. [PMID: 32989260 DOI: 10.1038/s41391-020-00288-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Revised: 09/09/2020] [Accepted: 09/16/2020] [Indexed: 11/09/2022]
Abstract
BACKGROUND Unlike in other mouse models of atherogenesis, it has recently been suggested that orchiectomy plays a role in accelerating atherosclerosis and inhibiting the progression of cardiovascular disease in the ApoE-/-:Ins2+/Akita mouse model of hyperglycemia. Androgen-deprivation therapy (ADT) is a common treatment for prostate cancer, a population with high prevalence of cardiovascular disease and its risk factors. Our objectives were to test and further characterize the effects of pharmacological castration which is currently the acceptable modality to deliver ADT in the clinic. METHODS Male ApoE-/-:Ins2+/Akita mice received one of three modes of ADT (gonadotropin-releasing hormone (GnRH)-antagonist (degarelix), GnRH-agonist (leuprolide), or bilateral orchiectomy) and were compared to corresponding untreated control mice (n = 9-13/group). Mice were followed for 5 months. Body weight, fasting blood glucose, glucose tolerance, serum C-peptide, leptin, and testosterone levels along with atherosclerotic aortic plaque size and characteristics were determined. In a separate experiment, the survival of mice, untreated and on ADT, was determined. RESULTS Castration was achieved for all three modes of ADT. However, degarelix-treated mice gained significantly less weight, had lower serum leptin levels and systolic blood pressure compared to orchiectomy and leuprolide-treated mice. ADT improved dysglycemia and atherosclerotic burden. GnRH-antagonist significantly improved survival compared to GnRH-agonist but not compared to orchiectomy. CONCLUSIONS Further characterization of the ApoE-/-:Ins2+/Akita mouse model confirms that pharmacological ADT ameliorated metabolic syndrome and cardiovascular complications. Improved dysglycemia and atherosclerosis associated with increased survival which was longest after degarelix followed by orchiectomy.
Collapse
Affiliation(s)
- Wilhelmina C M Duivenvoorden
- Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada.,Research Institute of St. Joe's, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
| | - Magda Naeim
- Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada
| | - Sarah N Hopmans
- Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada
| | - Sadiya Yousef
- Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada
| | - Geoff H Werstuck
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada.,Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada
| | - Shawn Dason
- Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada.,Department of Urology, The Ohio State University, Columbus, OH, USA
| | - Jehonathan H Pinthus
- Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada. .,Research Institute of St. Joe's, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
| |
Collapse
|
6
|
Crane ED, Al-Hashimi AA, Chen J, Lynn EG, Won KD, Lhoták Š, Naeim M, Platko K, Lebeau P, Byun JH, Shayegan B, Krepinsky JC, Rayner KJ, Marchiò S, Pasqualini R, Arap W, Austin RC. Anti-GRP78 autoantibodies induce endothelial cell activation and accelerate the development of atherosclerotic lesions. JCI Insight 2018; 3:99363. [PMID: 30568038 DOI: 10.1172/jci.insight.99363] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2017] [Accepted: 11/09/2018] [Indexed: 12/31/2022] Open
Abstract
The 78-kDa glucose-regulated protein (GRP78) is an ER molecular chaperone that aids in protein folding and secretion. However, pathological conditions that cause ER stress can promote the relocalization of GRP78 to the cell surface (csGRP78), where it acts as a signaling receptor to promote cancer progression. csGRP78 also possesses antigenic properties, leading to the production of anti-GRP78 autoantibodies, which contribute to tumor growth. In contrast, the presence and role of anti-GRP78 autoantibodies in atherosclerosis is unknown. Here, we show that atherosclerotic-prone ApoE-/- mice develop circulating anti-GRP78 autoantibodies that bind to csGRP78 on lesion-resident endothelial cells. Moreover, GRP78-immunized ApoE-/- mice exhibit a marked increase in circulating anti-GRP78 autoantibody titers that correlated with accelerated lesion growth. Mechanistically, engagement of anti-GRP78 autoantibodies with csGRP78 on human endothelial cells activated NF-κB, thereby inducing the expression of ICAM-1 and VCAM-1, a process blocked by NF-κB inhibitors. Disrupting the autoantibody/csGRP78 complex with enoxaparin, a low-molecular-weight heparin, reduced the expression of adhesion molecules and attenuated lesion growth. In conclusion, anti-GRP78 autoantibodies play a crucial role in atherosclerosis development, and disruption of the interaction between anti-GRP78 autoantibodies and csGRP78 represents a therapeutic strategy.
Collapse
Affiliation(s)
| | - Ali A Al-Hashimi
- Department of Medicine, Division of Nephrology, and.,Division of Urology, Department of Surgery, McMaster University and The Research Institute of St. Joe's Hamilton, Hamilton, Ontario, Canada
| | - Jack Chen
- Department of Medicine, Division of Nephrology, and
| | | | | | - Šárka Lhoták
- Department of Medicine, Division of Nephrology, and
| | - Magda Naeim
- Department of Medicine, Division of Nephrology, and
| | | | - Paul Lebeau
- Department of Medicine, Division of Nephrology, and
| | | | - Bobby Shayegan
- Division of Urology, Department of Surgery, McMaster University and The Research Institute of St. Joe's Hamilton, Hamilton, Ontario, Canada
| | | | - Katey J Rayner
- Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa and University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | - Serena Marchiò
- Department of Oncology, University of Turin, Candiolo, Italy.,Candiolo Cancer Institute - Fondazione del Piemonte per l'Oncologia, Istituto di Ricerca e Cura a Carattere Scientifico, Candiolo, Italy
| | - Renata Pasqualini
- Rutgers Cancer Institute of New Jersey, Newark, New Jersey, USA.,Division of Cancer Biology, Department of Radiation Oncology, and
| | - Wadih Arap
- Rutgers Cancer Institute of New Jersey, Newark, New Jersey, USA.,Division of Hematology/Oncology, Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA
| | - Richard C Austin
- Department of Biochemistry and Biomedical Sciences.,Department of Medicine, Division of Nephrology, and
| |
Collapse
|
7
|
Martín Carreras-Presas C, Naeim M, Hsiou D, Somacarrera Pérez ML, Messadi DV. The need to educate future dental professionals on E-cigarette effects. Eur J Dent Educ 2018; 22:e751-e758. [PMID: 30125441 DOI: 10.1111/eje.12390] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 07/20/2018] [Indexed: 06/08/2023]
Abstract
OBJECTIVE To compare knowledge and attitude of dental students in two countries towards E-cigarettes and their long-term effects. MATERIAL AND METHODS An anonymous cross-sectional survey, using self-administered questionnaires, was conducted amongst dental students from the University of California, Los Angeles School of Dentistry (UCLA) and Universidad Europea of Madrid (UE). RESULTS There were significant differences in knowledge and perception of E-cigarettes between dental students from both countries. Three (3%) of the participants from UE sample smoked E-cigarettes every day, compared to none of the students from UCLA. Almost 54 (80%) students from UCLA claimed that they had never experimented with an E-cigarette, whereas 61 (65%) of UE sample reported not having experimented with E-cigarettes in the past. More than 15% of students in both populations were unsure of the potentially harmful effects of E-cigarette usage. A significantly higher proportion of the Spanish sample used conventional cigarettes compared to the US sample 53 (56%) compared to 36 (24%), P < 0.001). In addition, when compared to the UE sample, UCLA students rated E-cigarettes as being less harmful overall than tobacco P < 0.001. Furthermore, more than 86% of both populations indicated interest in learning more about the potential risks associated with E-cigarettes. CONCLUSIONS This survey indicated that students from one dental school in the United States of America (USA) and one in Spain lacked the knowledge to address the rising E-cigarette population usage and provide information regarding them to patients. Specific educational programmes on E-cigarette hazards and long-term effects on oral and systemic health should be implemented in dental curricula in both of these schools in order to stay receptive to the changing field of tobacco education.
Collapse
Affiliation(s)
- C Martín Carreras-Presas
- Adult's Dentistry Department, Faculty of Biomedical Sciences, Universidad Europea of Madrid, Madrid, Spain
| | - M Naeim
- School of Dentistry, University of California, Los Angeles, California
| | - D Hsiou
- School of Dentistry, University of California, Los Angeles, California
| | - M L Somacarrera Pérez
- Section of Oral Medicine and Special Care Dentistry Department, Universidad Europea of Madrid, Madrid, Spain
| | - D V Messadi
- Section of Oral Medicine and Orofacial Pain, UCLA School of Dentistry, Los Angeles, California
| |
Collapse
|
8
|
Bassiouny D, Ismiil N, Dubé V, Han G, Cesari M, Lu FI, Slodkowska E, Parra-Herran C, Chiu HF, Naeim M, Li N, Khalifa M, Nofech-Mozes S. Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma. Int J Surg Pathol 2018; 26:306-317. [PMID: 29338553 DOI: 10.1177/1066896917752861] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/-, CDX2+/-, PAX8-, ER-, PgR-, and SATB2-. HER2 positivity suggests a possible target for therapy in advanced disease.
Collapse
Affiliation(s)
- Dina Bassiouny
- 1 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,2 University of Toronto, Toronto, Ontario, Canada.,3 Mansoura University, Mansoura, Egypt
| | - Nadia Ismiil
- 1 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,2 University of Toronto, Toronto, Ontario, Canada
| | - Valerie Dubé
- 1 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,2 University of Toronto, Toronto, Ontario, Canada
| | - Guangming Han
- 1 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,2 University of Toronto, Toronto, Ontario, Canada
| | - Matthew Cesari
- 1 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,2 University of Toronto, Toronto, Ontario, Canada
| | - Fang-I Lu
- 1 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,2 University of Toronto, Toronto, Ontario, Canada
| | - Elzbieta Slodkowska
- 1 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,2 University of Toronto, Toronto, Ontario, Canada
| | - Carlos Parra-Herran
- 1 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,2 University of Toronto, Toronto, Ontario, Canada
| | - Hak Fai Chiu
- 1 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Magda Naeim
- 1 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Nim Li
- 1 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Mahmoud Khalifa
- 1 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,2 University of Toronto, Toronto, Ontario, Canada
| | - Sharon Nofech-Mozes
- 1 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.,2 University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
9
|
Nam RK, Benatar T, Wallis CJD, Amemiya Y, Yang W, Garbens A, Naeim M, Sherman C, Sugar L, Seth A. MiR-301a regulates E-cadherin expression and is predictive of prostate cancer recurrence. Prostate 2016; 76:869-84. [PMID: 26990571 DOI: 10.1002/pros.23177] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2015] [Accepted: 02/18/2016] [Indexed: 12/16/2022]
Abstract
BACKGROUND MicroRNAs (miRNAs) are small, noncoding RNAs that regulate gene expression post-transcriptionally. Dysregulation of miRNA has been implicated in the development and progression of prostate cancer. Through next generation miRNA sequencing, we recently identified a panel of five miRNAs associated with prostate cancer recurrence and metastasis. Of the five miRNAs, miR-301a had the strongest association with prostate cancer recurrence. Overexpression of miR-301a in prostate cancer cells, PC3, and LNCaP resulted in increased growth both in vitro and in xenografted tumors. We therefore sought to examine its role in prostate carcinogenesis in greater detail. METHODS We examined the effect of miR-301a expression on biochemical recurrence and metastasis among 585 men treated with radical prostatectomy for prostate cancer. We examined the mechanism of growth deregulation by miR-301a in prostate cancer cells using analysis of the miRome of prostate cancer cell lines, quantitative PCR, and Western blotting. RESULTS High levels of miR-301a (above the median) were associated with an increased risk of biochemical recurrence (adjusted hazard ratio [aHR] 1.42, 95% confidence interval (CI) 1.06-1.90, P = 0.002) but not of metastasis (aHR 0.84, 95%CI 0.41-1.70, P = 0.6) after adjustment for known prognostic factors. RNA transcriptome sequencing analysis of miR-301a overexpressing prostate cancer cell lines identified the tumor suppressor p63 as a potential direct miR-301a target. Transcriptome sequencing, qPCR and Western blotting showed that miR-301a induced epithelial-mesenchymal transition (EMT) in prostate cancer cells through a pathway initiated by p63 inhibition. Luciferase assay verified p63 as a direct target of miR-301a. Loss of p63 resulted in miR-205 downregulation, releasing Zeb1 and Zeb2 from inhibition, culminating in Zeb1/Zeb2 suppression of E-cadherin. This pathway of growth alteration mediated by miR-301a upregulation was shown to be valid in prostate cancer cell lines and patient-derived tumors. CONCLUSIONS These data indicate that miR-301a functions as an oncogene in prostate cancer by directly targeting the p63 tumor suppressor leading to loss of E-cadherin and EMT. Hence, miR-301a may serve as a novel biomarker in prostate cancer as well as a therapeutic target for prostate cancer management. Prostate 76:869-884, 2016. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Robert K Nam
- Division of Urology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
| | - Tania Benatar
- Department of Anatomic Pathology, Platform Biological Sciences, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
| | - Christopher J D Wallis
- Division of Urology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
| | - Yutaka Amemiya
- Department of Anatomic Pathology, Platform Biological Sciences, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
| | - Wenyi Yang
- Department of Anatomic Pathology, Platform Biological Sciences, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
| | - Alaina Garbens
- Division of Urology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
| | - Magda Naeim
- Department of Laboratory Medicine and Pathobiology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
| | - Christopher Sherman
- Department of Laboratory Medicine and Pathobiology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
| | - Linda Sugar
- Department of Laboratory Medicine and Pathobiology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
| | - Arun Seth
- Department of Anatomic Pathology, Platform Biological Sciences, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
10
|
Nam RK, Amemiya Y, Benatar T, Wallis CJD, Stojcic-Bendavid J, Bacopulos S, Sherman C, Sugar L, Naeim M, Yang W, Zhang A, Klotz LH, Narod SA, Seth A. Identification and Validation of a Five MicroRNA Signature Predictive of Prostate Cancer Recurrence and Metastasis: A Cohort Study. J Cancer 2015; 6:1160-71. [PMID: 26516365 PMCID: PMC4615353 DOI: 10.7150/jca.13397] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Accepted: 08/02/2015] [Indexed: 01/01/2023] Open
Abstract
Background: MicroRNA (miRNA) have been shown to be important in regulating gene expression in prostate cancer. We used next generation miRNA sequencing to conduct a whole miRNome analysis to identify miRNAs associated with prostate cancer metastasis. Methods: We conducted discovery and validation analyses of miRNAs among a total of 546 men who underwent surgery for prostate cancer using the development of metastasis as an endpoint. Genome wide analysis was conducted among the discovery group (n=31) to identify new miRNAs associated with prostate cancer metastasis. Selected miRNAs were then analyzed using qPCR on prostatectomy specimens from an independent cohort (n=515) to determine whether their expression could predict the development of metastasis after surgery. To examine the biology underlying these associations, we created prostate cancer cell lines which overexpressed miR-301a for in vitro and in vivo functional assays. Results: We identified 33 miRNAs associated with prostate cancer metastasis and selected a panel comprising miRs-301a, 652, 454, 223 and 139 which strongly predicted metastasis (AUC=95.3%, 95%C.I.:84%-99%). Among the validation cohort, the 15-year metastasis-free survival was 77.5% (95% C.I.:63.9%-86.4%) for patients with a high miRNA panel score and 98.8% (95% C.I.:94.9%-99.7%, p<0.0001 for difference) for those with a low score. After adjusting for grade, stage, and PSA, the hazard ratio for metastasis was 4.3 (95% C.I.: 1.7-11.1, p=0.002) for patients with a high miRNA panel score, compared to those with a low score. Prostate cancer cell lines overexpressing miR-301a had in significantly higher tumor growth and metastasis in a xenograft mouse model. Conclusions: A panel of miRNAs is associated with prostate cancer metastasis. These could be used as potential new prognostic factors in the surgical management of prostate cancer.
Collapse
Affiliation(s)
- Robert K Nam
- 1. Division of Urology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave., Toronto, ON, M4N3M5, Canada
| | - Yutaka Amemiya
- 2. Department of Anatomic Pathology, Platform Biological Sciences, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave., Toronto, ON, M4N3M5, Canada
| | - Tania Benatar
- 2. Department of Anatomic Pathology, Platform Biological Sciences, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave., Toronto, ON, M4N3M5, Canada
| | - Christopher J D Wallis
- 1. Division of Urology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave., Toronto, ON, M4N3M5, Canada
| | - Jessica Stojcic-Bendavid
- 1. Division of Urology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave., Toronto, ON, M4N3M5, Canada
| | - Stephanie Bacopulos
- 2. Department of Anatomic Pathology, Platform Biological Sciences, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave., Toronto, ON, M4N3M5, Canada
| | - Christopher Sherman
- 3. Department of Laboratory Medicine and Pathobiology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave., Toronto, ON, M4N3M5, Canada
| | - Linda Sugar
- 3. Department of Laboratory Medicine and Pathobiology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave., Toronto, ON, M4N3M5, Canada
| | - Magda Naeim
- 3. Department of Laboratory Medicine and Pathobiology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave., Toronto, ON, M4N3M5, Canada
| | - Wenyi Yang
- 2. Department of Anatomic Pathology, Platform Biological Sciences, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave., Toronto, ON, M4N3M5, Canada
| | - Aiguo Zhang
- 2. Department of Anatomic Pathology, Platform Biological Sciences, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave., Toronto, ON, M4N3M5, Canada
| | - Laurence H Klotz
- 1. Division of Urology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave., Toronto, ON, M4N3M5, Canada
| | - Steven A Narod
- 4. Department of Public Health Sciences, University of Toronto, 790 Bay St., Toronto, ON, M5G 1N8, Canada
| | - Arun Seth
- 2. Department of Anatomic Pathology, Platform Biological Sciences, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave., Toronto, ON, M4N3M5, Canada
| |
Collapse
|